Clinical Trial Update: CD8 Minibody Repeatability Study [Phase 2]

View source ↗

Summary

ImaginAb's Phase 2 CD8 minibody repeatability study in melanoma and renal cell carcinoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma
• Renal Cell Carcinoma

Drugs mentioned

• CD8 minibody (CD8 minibody)

Snippet

Sponsor: ImaginAb, Inc. | Conditions: Melanoma, Renal Cell Carcinoma | Phase 2 | Status: TERMINATED